Related Experiment Video
Updated: Apr 19, 2026
07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
2.2K
JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based
Jeng-Wei Lu1, Yi-Jung Ho2, Liang-In Lin3
1Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
Acta Histochemica
|December 24, 2014
Summary
This study found JMJD2B protein is highly expressed in hepatocellular carcinoma (HCC). Upregulated JMJD2B correlates with HCC
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Hepatocellular carcinoma (HCC) is a significant global health concern.
- Identifying novel biomarkers for HCC diagnosis and prognosis is crucial.
Purpose of the Study:
- To investigate the expression of JMJD2B in human hepatocellular carcinoma (HCC).
- To correlate JMJD2B expression patterns with clinicopathological parameters in HCC patients.
Main Methods:
- Immunohistochemical staining was employed to detect JMJD2B expression.
- Tissue microarrays from various human cancers, including liver cancer, were analyzed.
- Correlation analysis was performed with clinicopathological features and Ki-67 expression.
Main Results:
- JMJD2B protein levels were significantly upregulated in malignant tumors, including liver cancer.
- Increased JMJD2B expression in HCC correlated with histological grade and TNM stage.
- JMJD2B expression showed a positive correlation with Ki-67 expression in HCC samples.
Conclusions:
- JMJD2B is dramatically upregulated in hepatocellular carcinoma.
- JMJD2B serves as a potential diagnostic marker for HCC.
- Further research into JMJD2B could advance HCC treatment strategies.
